CARD19

Across TCGA pan-cancer cohorts, CARD19 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of CARD19’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CARD19 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CARD19 is over-expressed in tumor, although a few such as PRAD show the opposite, repressed pattern.

HNSC, KIRC, and COAD are the cancer types where CARD19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CARD19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	III,IV	+1.288	<.001	11	view →
KIRC	Female	All	+0.613	<.001	11	view →
COAD	All	IV	+0.922	<.001	10	view →
LIHC	Female	II,III,IV	+1.028	<.001	9	view →
KIRP	All	III,IV	+0.879	<.001	8	view →
BRCA	All	III,IV	+0.760	<.001	6	view →
CHOL	All	All	+1.527	<.001	5	view →
STAD	All	II,III,IV	+0.534	.001	5	view →
ESCA	All	All	+1.205	<.001	3	view →
LUSC	All	All	+0.337	<.001	3	view →
THCA	Female	All	+0.289	<.001	2	view →
PRAD	All	All	−0.262	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

CARD19–HNSC

Open the HNSC breakdown →